Stem Cell Therapeutics Corp. Announces First Quarter 2009 Financial Results

Stem Cell Therapeutics Corp. ("SCT") (TSX VENTURE:SSS) today announced its
financial results for the period ended March 31, 2009.


Highlights from the first quarter of 2009 and up to May 27, 2009

- Detailed and cooperative work with the FDA resulted in the lift of the
clinical hold on the Phase IIb clinical stroke trial, as announced on May 14,
2009


- Completion of an animal study that indicated a positive result for using an
extended human Chorionic Gonadotropin ("hCG") treatment for stroke


- Released encouraging data from 7 patients enrolled in the original REGENESIS
stroke trial prior to the clinical hold, as announced May 21, 2009


Financial Review

The Company's loss for the three month period ended March 31, 2009 decreased by
$469,427 to $884,759 ($0.01 per common share) from the loss of $1,354,186 ($0.01
per common share) reported for the three month period ended March 31, 2008. The
primary reason for the decrease in loss was decreases in general and
administration expenses, research and development costs and management and
consulting fees offset by a decrease in interest income earned during the
period.


Capital Position

As of March 31, 2009 the working capital (current assets minus current
liabilities) of the Company was $5,072,798 ($5,803,377 as of December 31, 2008).
Outstanding securities as of March 31, 2009 totaled 132,802,497 common shares
18,975,000 share purchase warrants and 12,121,103 common share options.


Dr. Alan Moore, President and CEO of SCT commented as follows:

"Throughout the first quarter of 2009 we continued to work with the FDA and our
efforts were recognized on May 14, 2009 when the clinical hold on our NTx(R)-265
Phase IIb clinical stroke trial was lifted. We were also encouraged by an animal
study indicating extended hCG treatments have activity in a key animal model for
stroke. This is an important addition to our intellectual property inventory.
And, the results from the seven patients enrolled in the REGENESIS study prior
to the clinical hold provide further encouragement for the efficacy of our
product. Finally, we were successful with our cost-cutting initiative as we have
been able to preserve enough capital to take us through the completion of the
modified Phase IIb stroke trial."


About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp. is a Canadian
public biotechnology company (TSX VENTURE:SSS) focused on the development and
commercialization of drug-based therapies to treat central nervous system
diseases. SCT is a leader in the development of therapies that utilize drugs to
stimulate a patient's own resident stem cells. The Company's programs aim to
repair brain and nerve function lost due to disease or injury. The Company's
extensive patent portfolio of owned and licensed intellectual property supports
the potential expansion into future clinical programs in numerous neurological
diseases such as traumatic brain injury, multiple sclerosis, Huntington's
disease, Alzheimer's disease, and ALS.


These securities have not been registered under the United States Securities Act
of 1933, as amended, or the securities laws of any state, and may not be offered
or sold within the United States or to, or for the account or benefit of U.S.
persons unless an applicable exemption from U.S. registration requirements is
available.


Except for historical information, this press release may contain
forward-looking statements, which reflect the Company's current expectation
regarding future events. These forward-looking statements involve risk and
uncertainties, which may cause but are not limited to, changing market
conditions, the successful and timely completion of clinical studies, the
establishment of corporate alliances, the impact of competitive products and
pricing, new product development, uncertainties related to the regulatory
approval process and other risks detailed from time to time in the Company's
ongoing quarterly and annual reporting.